Literature DB >> 19748495

Impaired blood-brain and blood-spinal cord barriers in mutant SOD1-linked ALS rat.

Charles Nicaise1, Dinko Mitrecic, Pieter Demetter, Robert De Decker, Michèle Authelet, Alain Boom, Roland Pochet.   

Abstract

Blood-brain barrier (BBB) and blood-spinal cord barrier (BSCB) impairment is an additional accident occurring during the amyotrophic lateral sclerosis (ALS) progression. In this work, we aimed to decipher if BBB/BSCB leakage appeared before critical detrimental events and could serve as a marker preceding clinical symptoms. Three different BBB leakage markers: Evans blue, IgG and hemosiderin, were used to look at the SOD1-linked ALS rat model at presymptomatic and symptomatic stages. Although IgG and hemosiderin could be detected at presymptomatic stage, Evans blue extravasation which fits best with BBB/BSCB impairment could only be seen at symptomatic stages. BBB/BSCB impairment was further substantiate by showing at symptomatic stages decreased mRNA expression of ZO-1 and occludin as well as agrin, a basal membrane constituent. Electron microscopic data substantiate a toxic environment around endothelial cell and peri-vascular swollen astrocyte end-feet showing oedema-linked BBB opening.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19748495     DOI: 10.1016/j.brainres.2009.09.018

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  61 in total

Review 1.  Blood-Brain Barrier Driven Pharmacoresistance in Amyotrophic Lateral Sclerosis and Challenges for Effective Drug Therapies.

Authors:  Loqman A Mohamed; Shashirekha Markandaiah; Silvia Bonanno; Piera Pasinelli; Davide Trotti
Journal:  AAPS J       Date:  2017-08-04       Impact factor: 4.009

2.  Dendritic degeneration, neurovascular defects, and inflammation precede neuronal loss in a mouse model for tau-mediated neurodegeneration.

Authors:  Tomasz Jaworski; Benoit Lechat; David Demedts; Lies Gielis; Herman Devijver; Peter Borghgraef; Hans Duimel; Fons Verheyen; Sebastian Kügler; Fred Van Leuven
Journal:  Am J Pathol       Date:  2011-08-10       Impact factor: 4.307

3.  Blood cells and endothelial barrier function.

Authors:  Stephen F Rodrigues; D Neil Granger
Journal:  Tissue Barriers       Date:  2015-04-03

Review 4.  Transplantation of stem cell-derived astrocytes for the treatment of amyotrophic lateral sclerosis and spinal cord injury.

Authors:  Charles Nicaise; Dinko Mitrecic; Aditi Falnikar; Angelo C Lepore
Journal:  World J Stem Cells       Date:  2015-03-26       Impact factor: 5.326

5.  Defective neuromuscular transmission in the SOD1 G93A transgenic mouse improves after administration of human umbilical cord blood cells.

Authors:  Nizar Souayah; K M Coakley; R Chen; Norman Ende; Joseph J McArdle
Journal:  Stem Cell Rev Rep       Date:  2012-03       Impact factor: 5.739

Review 6.  Agile delivery of protein therapeutics to CNS.

Authors:  Xiang Yi; Devika S Manickam; Anna Brynskikh; Alexander V Kabanov
Journal:  J Control Release       Date:  2014-06-21       Impact factor: 9.776

7.  Immunological aspects in amyotrophic lateral sclerosis.

Authors:  Maria Carolina O Rodrigues; Júlio C Voltarelli; Paul R Sanberg; Cesario V Borlongan; Svitlana Garbuzova-Davis
Journal:  Transl Stroke Res       Date:  2012-05-03       Impact factor: 6.829

8.  Neuronal glucose metabolism is impaired while astrocytic TCA cycling is unaffected at symptomatic stages in the hSOD1G93A mouse model of amyotrophic lateral sclerosis.

Authors:  Tesfaye W Tefera; Karin Borges
Journal:  J Cereb Blood Flow Metab       Date:  2018-03-19       Impact factor: 6.200

Review 9.  Brain metabolism in health, aging, and neurodegeneration.

Authors:  Simonetta Camandola; Mark P Mattson
Journal:  EMBO J       Date:  2017-04-24       Impact factor: 11.598

10.  Reduction of circulating endothelial cells in peripheral blood of ALS patients.

Authors:  Svitlana Garbuzova-Davis; Robert L Woods; Michael K Louis; Theresa A Zesiewicz; Nicole Kuzmin-Nichols; Kelly L Sullivan; Amber M Miller; Diana G Hernandez-Ontiveros; Paul R Sanberg
Journal:  PLoS One       Date:  2010-05-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.